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Introduction
The adoptive cell transfer (ACT) of autologous tumor
infiltrating lymphocytes (TIL) can mediate durable,
complete tumor regression in approximately 20% of
patients with metastatic melanoma. Recent observations
suggest that autologous melanoma TIL administered to
multiple patients in ACT protocols can recognize 1 or
more tumor-specific somatic mutations, findings facili-
tated by recent advances in whole exome sequencing
and RNA-seq methods.
Methods
In an attempt to evaluate the antigenic diversity of TIL
and gain some insights into the potential association
between the recognition of mutated antigens and clinical
responses to TIL therapy, we analyzed between 5 and 30
individual cultures derived from resected melanoma
tumor fragments and pooled populations of adminis-
tered TIL from each patient for their ability to recognize
mutated antigens expressed by patients’ tumors. Samples
from 11 patients evaluated in this initial study include
5 who exhibited durable complete tumor regressions,
1 who exhibited a partial response, and 5 who were
non-responders to ACT. Screening assays were carried
out by evaluating the interferon gamma release stimu-
lated by the co-culture of patient TIL with autologous
dendritic cells or EBV transformed B cells that were
transfected with up to sixty two tandem mini-genes
encoding mutated antigens identified by sequencing
patient tumors.
Results
Using this approach, we were able to identify between
2 to 11 mutated antigens per patient that were targeted
by TIL in 9 of the 11 patients. The TIL generated from
2 of the 5 patients who did not respond to ACT failed
to recognize any mutated antigens tested, but recog-
nized an autologous tumor cell line. For each of the
9 patients demonstrating mutated antigen reactivity, at
least 1 immuno-dominant mutated antigen was recognized
by the majority of the evaluated TIL fragment cultures and
the bulk infusion TIL, and 1 or more sub-dominant
mutated antigens recognized by one or a relatively small
percentage of the screened TIL fragment cultures could be
identified. Future studies will be directed at developing
approaches to tumor immunotherapy based upon the iden-
tification and isolation of T cells reactive with mutated
epitopes.
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